Development and Opportunities for RNA Drug

发布者：滕昕辰发布时间：2022-12-03浏览次数：80

Topic: Development and Opportunities for RNA Drug

Speaker: Peizhuo Zhang, President of Suzhou GenePharma Co., LTD

Time: 18:30-19:30 on Sunday, December 4, 2022

Location: Tencent Conference 764513463

 

About the Speaker

Peizhuo Zhang got his Ph.D. in medicinal chemistry from Beijing Medical University and was a Postdoctoral Fellow in nucleic acid Chemistry at King's College London.

After returning to China in 2003, he founded Shanghai GenePharma Co., Ltd., and Suzhou GenePharma Co., Ltd., mainly engaged in constructing RNAi (RNA interference) drug production technology platforms and the research and development for new drugs and diagnostic reagents. After several years of hard work, the company has established an upstream and downstream RNAi drug industry chain from critical raw materials to API synthesis. The company has customized several RNAi drugs and related reagents for treating different diseases for scientific research institutions and pharmaceutical factories, becoming a leading enterprise in the field of RNAi-related products in China. Its main product, small interfering nucleic acid (siRNA), accounts for more than half of the domestic market share. It is one of only a few major global suppliers of large-scale synthesized siRNA and RNA monomers. As the only Chinese company, it has been included in the RNAi Global Market Report by Jain PharmaBioTech, an internationally renowned market research company, and listed as one of the rising stars of Chinese biotechnology by Forbes Chinese magazine. CCTV News Broadcast, Oriental TV, Xinhuanet, and other media have also made special interviews and reports on Gemma Company.

He served as the vice president of the Jiangsu Small nucleic acid Industry Alliance, the vice president of the Jiangsu Nano Industry Alliance, the vice president of the Jiangsu Medical Industry Alliance, and the chairman of the Suzhou Nano biomedicine Industry Alliance. He was a deputy of the Suzhou Municipal People's Congress and was awarded the Suzhou Outstanding Talent Award in 2014.